MedTrace Logo

S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)

NCT01061437 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1859

Last updated 2012-09-26

No results posted yet for this study

Summary

The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

PACx14

Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)

DRUG

PACMx5

Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)

DRUG

PAx5/PCMx5

Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • E. Robert Greenberg, M.D. · SWOG Cancer Research Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Chile
  • Colombia
  • Costa Rica
  • Honduras
  • Mexico
  • Nicaragua

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01061437 on ClinicalTrials.gov